Targeting Bcl-2/Bcl-X L induces antitumor activity in uveal melanoma patient-derived xenografts

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Némati, Fariba ^a   De Montrion, Catherine ^b   Lang, Guillaume ^a   Kraus Berthier, Laurence ^b   Carita, Guillaume ^a   Sastre Garau, Xavier ^a   Berniard, Aurélie ^a   Vallerand, David ^a   Geneste, Olivier ^b   De Plater, Ludmilla ^a   Pierré, Alain ^b   Lockhart, Brian ^b   Desjardins, Laurence ^a   Piperno Neumann, Sophie ^a   Depil, Stéphane ^b   Decaudin, Didier ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOTEMUSTINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; S 44563; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TUMOR XENOGRAFT; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; CELL PROLIFERATION; FLUORESCENCE POLARIZATION; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PEPTIDES; PROTEIN BINDING; SURVIVAL ANALYSIS; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897976769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080836     Document Type: Article

References (49)

1. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, et al. (1998) Treatment of liver metastases from melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 24: 127-130. (Pubitemid 28205941)
2. Kujala E, Mäkitie T, Kivelä T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Ophthalmology 110: 962-965.
3. Augsburger JJ, Corrêa ZM, Shaikh AH (2009) Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 148: 119-127.
4. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
5. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116: 205-219. (Pubitemid 38167313)
6. Mooy CM, Luyten GP, de Jong PT, Luider TM, Stijnen T, et al. (1995) Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 147: 1097-1104.
7. Jay V, Yi Q, Hunter WS, Zielenska M (1996) Expression of bcl-2 in uveal malignant melanoma. Arch Pathol Lab Med 120: 487-488.
8. Coupland SE, Bechrakis N, Schüler A, Anagnostopoulos I, Hummel M, et al. (1998) Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 82: 961-970. (Pubitemid 28408159)
9. Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, et al. (1999) c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 83: 110-114. (Pubitemid 29106343)
10. Lawry J, Currie Z, Smith MO, Rennie IG (1999) The correlation between cell surface markers and clinical features in choroidal malignant melanomas. Eye 13: 301-308. (Pubitemid 29338860)
11. Sulkowska M, Famulski W, Bakunowicz-Lazarczyk, Chyczewski L, Sulkowski S (2001) Bcl-2 expression in primary uveal melanoma. Tumori 87: 54-57. (Pubitemid 32273853)
12. Hussein MR (2005) Analysis of Bcl-2 protein expression in choroidal melanomas. J Clin Pathol 58: 486-489.
13. Némati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, et al. (2010) Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 16: 2352-2362.
14. Resik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885.
15. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745. (Pubitemid 46630937)
16. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, et al. (2009) 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 27: 5208-5212.
17. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, et al. (2008) Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26: 870-876. (Pubitemid 351398078)
18. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, et al. (2009) Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 50: 559-565.
19. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, et al. (2009) Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20: 1264-1269.
20. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681. (Pubitemid 40825512)
21. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
22. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104: 19512-19517.
23. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. (2010) The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66: 869-880.
24. Tan N, Malek M, Zha J, Yue P, Kassees R, et al. (2011) Navotoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 17: 1394-1404.
25. L inhibition in small cell lung cancer. A new concept of using radiation for targeted therapy through contextual oncogene addiction. Am Assoc Cancer Res Annual congress: poster 4891.
26. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, et al. (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29: 909-916.
27. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, et al. (2011) Nanitoclax, a targeted high-affinity inhibitor of Bcl-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11: 1149-1159.
28. Guo LJ, Wu ZY, Zhang S, Zheng JL, Zheng hL (2003) Effect of bcl-2 antisense oligonucleotides on multidrug resistance of cultured uveal melanoma cells. Zhonghua Yan Ke Za Zhi 39: 73-76.
29. Laurent C, Gentien D, Piperno-Neumann S, Némati F, Nicolas A, et al. (2013) Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol Oncol 7: 625-636.
30. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B (2009) Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res 15: 6096-6105.
31. Weber A, Kirejczyk Z, Potthoff S, Ploner C, Häcker G (2009) Endogenous Noxa determines the strong proapoptotic synergism of the BH3-mimetic ABT-737 with chemotherapeutic agents in human melanoma cells. Translat Oncol 2: 73-83.
32. Reuland SN, Goldstein NB, Partyka KA, Cooper DA, Fujita M, et al. (2011) The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One 6: e24294.
33. Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, et al. (2007) The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergsitic effect with dexamethasone and melphalan. Clin Cancer Res 13: 621-629. (Pubitemid 46225369)
34. low profile and synergizes with other antineoplastic agents. Clin Cancer Res 17: 5973-5981.
35. Zhou Z, Zhang C, Xia C, Chen W, Zhu H, et al. (2011) Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther 10: 1264-1275.
36. Xu H, Krystal GW (2010) Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clin Cancer Res 16: 4392-4400.
37. Jain HV, Meyer-Hermann M (2011) The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas. Cancer Res 71: 705-715.
38. Simoes-Wüst AP, Schürpf T, Hall J, Stahel RA, Zangemeister-Wittke U (2002) Bcl-2:bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat 76: 157-166. (Pubitemid 35252493)
39. Pepper C, Hooper K, Thomas A, Hoy T, Bentley P (2001) Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma 42: 491-498. (Pubitemid 32725605)
40. Zall H, Weber A, Besch R, Zantl N, Häcker G (2010) Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer 9: 164.
41. Yecies D, Carlson NE, Denq J, Letai A (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate Mcl-1 and BFL-1. Blood 115: 3304-3313.
42. Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, et al. (2011) An antiapoptotic Bcl-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 118: 3579-3590.
43. Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, et al. (2012) Modulation of NOXA and MLC-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 18: 783-795.
44. Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, et al. (2010) The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8: 1002-1016.
45. Malik SA, Orhon I, Morselli E, Criollo A, Shen S, et al. (2011) BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 30: 3918-3929.
46. Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, et al. (2008) Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 18: 220-224. (Pubitemid 351684668)
47. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, et al. (2006) Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17: 578-583.
48. Prescher G, Borngeld N, Horsthemke B, Becher R (1992) Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet 339: 691-692.
49. Trolet J, Hupé P, Huon I, Lebigot I, Decraene C, et al. (2009) Genomic profiling and identification of high-risk uveal melanoma by array cgh analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 50: 2572-2580.